Samsung Biologics (207940) Q1 2026 earnings summary

Executive summary

• Achieved 26% year-over-year revenue growth in Q1 2026, marking 27 consecutive quarters of YoY growth.

• Operating profit rose 35% YoY, with operating margin improving to 46.2%.

• Full utilization of Plants 1 to 4 and ramp-up of Plant 5 supported strong performance.

• Completed acquisition of a US manufacturing facility, expanding global footprint.

• Secured new CMO and CDO projects, surpassing 440 cumulative CMO product approvals.

Financial highlights

• Q1 2026 revenue: KRW 1,257B, up from KRW 1,000B in Q1 2025 (+26%).

• Operating profit: KRW 581B, up from KRW 430B (+35%).

• Net profit: KRW 331B, up from KRW 202B (+63.9%).

• EBITDA: KRW 675B, EBITDA margin 53.7% (up 2.2 percentage points YoY).

Outlook and guidance

• On track to meet annual guidance, supported by full operation of existing plants and Plant 5 ramp-up.

• Forecasted annual revenue growth of 15-20%.